Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHOENIX, JULY 17, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY SPECIALIZING IN REGENERATIVE MEDICINE, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A U.S. PATENT APPLICATION TITLED, PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES BY AUGMENTATION OF MYELOID SUPPRESSOR CELL ACTIVITY.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS RECEIVES NOTICE OF ALLOWANCEFOR THE PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES USING MODULATED IMMUNE CELLS

PHOENIX, JULY 11, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY SPECIALIZING IN REGENERATIVE MEDICINE, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A U.S. PATENT APPLICATION TITLED, TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS RECEIVES NOTICE OF ALLOWANCE FOR IMMCELZ FOR TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING

POSITIVE INTERIM BLINDED DATA SUPPORTS ADVANCEMENT TOWARDPOTENTIAL PIVOTAL PHASE 3 STUDY POSITIVE INTERIM BLINDED DATA SUPPORTS ADVANCEMENT TOWARDPOTENTIAL PIVOTAL PHASE 3 STUDY

CREATIVE MEDICAL TECHNOLOGY HOLDINGS SECURES FDA CLEARANCE FOR EXPANDED DOSE ESCALATION IN THE CLINICAL TRIAL OF CELZ-201-DDT FOR CHRONIC LOWER BACK PAIN

PHOENIX, MARCH 06, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., (NASDAQ: CELZ) (THE COMPANY), A LEADING BIOTECHNOLOGY INNOVATOR IN REGENERATIVE MEDICINE, TODAY ANNOUNCED IT HAS ENTERED INTO AGREEMENTS WITH CERTAIN HOLDERS OF ITS EXISTING WARRANTS FOR THE IMMEDIATE EXERCISE OF CERTAIN OUTSTANDING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 837,104 SHARES OF COMMON STOCK OF THE COMPANY ORIGINALLY ISSUED IN OCTOBER 2024 AT THEIR CURRENT EXERCISE PRICE OF $4.42 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT ON FORM S-1 (FILE NO. 333-283091). THE AGGREGATE GROSS PROCEEDS FROM THE EXERCISE OF THE EXISTING WARRANTS IS EXPECTED TO TOTAL APPROXIMATELY $3.7 MILLION, BEFORE DEDUCTING FINANCIAL ADVISORY FEES.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES AGREEMENTSFOR EXERCISE OF WARRANTSFOR $3.7 MILLION GROSS PROCEEDS

PHOENIX, FEB. 14, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. ("CREATIVE MEDICAL TECHNOLOGY" OR THE "COMPANY") (NASDAQ: CELZ), A PIONEERING BIOTECHNOLOGY FIRM SPECIALIZING IN REGENERATIVE MEDICINE SOLUTIONS FOR IMMUNOTHERAPY, ENDOCRINOLOGY, UROLOGY, GYNECOLOGY, AND ORTHOPEDICS, TODAY ANNOUNCED COMPELLING MID-TERM FOLLOW-UP DATA FROM ITS STEMSPINE PILOT STUDY UTILIZING ITS ALLOSTEM CELLS FOR THE TREATMENT OF CHRONIC LOWER BACK PAIN. THE PILOT STUDY DEMONSTRATED A SUBSTANTIAL REDUCTION IN OPIOID DEPENDENCY AND SIGNIFICANT IMPROVEMENTS IN PAIN LEVELS AND FUNCTIONAL MOBILITY.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES MID-TERM FOLLOW-UP STUDY DATA REPORTING SIGNIFICANT REDUCTION IN OPIOID USE BY CHRONIC LOWER BACK PAIN PATIENTS UNDERGOING STEMSPINE PROCEDURE USING ALLOSTEM

SIGNIFICANT EFFICACY AND NO SERIOUS ADVERSE EFFECTS OBSERVED WITH CELZ-201 SIGNIFICANT EFFICACY AND NO SERIOUS ADVERSE EFFECTS OBSERVED WITH CELZ-201

CREATIVE MEDICAL TECHNOLOGY REPORTS POSITIVE ONE-YEAR RESULTS FOR ALLOSTEM TYPE 2 DIABETES PROGRAM

PHOENIX, FEB. 05, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING REGENERATIVE MEDICINE SOLUTIONS, TODAY ANNOUNCED AN EXPANDED AGREEMENT WITH GREENSTONE BIOSCIENCES INC. (GREENSTONE) TO LEVERAGE ARTIFICIAL INTELLIGENCE (AI) IN FURTHER DEVELOPING ITS HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC) PLATFORM FOR DIABETES TREATMENT.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS EXPANDS COLLABORATION WITH GREENSTONE BIOSCIENCES TO ACCELERATE IPSCELZ PIPELINE DEVELOPMENT

PHOENIX, JAN. 30, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON REGENERATIVE MEDICINE, TODAY ANNOUNCED PROMISING INITIAL DATA FROM THE FIRST COHORT OF ITS ONGOING PHASE 1/2 CLINICAL TRIAL OF CELZ-201-DDT, THE COMPANY'S PROPRIETARY STEM CELL-BASED THERAPEUTIC FOR THE TREATMENT OF CHRONIC BACK PAIN CAUSED BY DEGENERATIVE DISC DISEASE (DDD).

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, AND EFFICACY DATA FROM FIRST COHORT IN PHASE 1/2 TRIAL OF CELZ-201-DDT FOR CHRONIC BACK PAIN

PHOENIX, NOV. 13, 2024 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ), A BIOTECHNOLOGY LEADER IN REGENERATIVE MEDICINE, IS PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF AN INDEPENDENT INTERIM SAFETY REVIEW BY THE DATA SAFETY MONITORING BOARD (DSMB) FOR ITS ADAPT CLINICAL TRIAL. THE TRIAL EVALUATED CELZ-201, A NOVEL THERAPEUTIC PERINATAL TISSUE DERIVED CELL PRODUCT, DESIGNED TO TREAT CHRONIC LOWER BACK PAIN ASSOCIATED WITH DEGENERATIVE DISC DISEASE.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. ADVANCES FDA CLEARED ADAPT CLINICAL TRIAL WITH POSITIVE INDEPENDENT REVIEW, VALIDATING THE SAFETY AND POTENTIAL OF CELZ-201 FORCHRONIC LOWER BACK PAIN TREATMENT

PHOENIX, JULY 24, 2024 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CREATIVE MEDICAL TECHNOLOGY OR THE COMPANY) (NASDAQ: CELZ), A LEADING COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON A REGENERATIVE APPROACH TO IMMUNOTHERAPY, UROLOGY, NEUROLOGY, AND ORTHOPEDICS, TODAY ANNOUNCED THAT IT HAS INITIATED ITS PLANNED PROGRAM TO DIAGNOSE AND TREAT PATIENTS EXPOSED TO BIOLOGICAL AND CHEMICAL WEAPONS BY COMBINING ARTIFICIAL INTELLIGENCE (AI) WITH THE COMPANY'S PROPRIETARY HUMAN INDUCED PLURIPOTENT STEM CELLS (IPSC). THIS IPSC CLINICAL LINE IS PART OF THE COMPANY'S IPSCELZ PROGRAM.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INITIATES DEVELOPMENT OF AI-DRIVEN DIAGNOSTIC AND TREATMENT PROGRAM FOR BIOLOGIC AND CHEMICAL EXPOSURE UTILIZING ITS VALIDATED IPSC PERSONALIZED MEDICINE PROGRAM

Creative Medical Technology Holdings, Inc.

CELZ

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Creative Medical Technology Holdings, Inc.

CELZ.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CELZ